Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SHR-A2102 versus investigator's choice chemotherapy in recurrent or metastatic cervical cancer after platinum chemotherapy and PD-(L)1 inhibitor failure
CTR20260558Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-A2102 in Cervical Cancer (CC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Mar 2026; status: active.
02
Drugs
SHR-A2102
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20260558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260558.